The Conversation (0)
October 20, 2025
INN Article Notification
22 December 2025
Hanlim & Korean Government Fund Pathway to Clinical Trial
Invion Limited (IVX:AU) has announced Hanlim & Korean Government Fund Pathway to Clinical TrialDownload the PDF here. Keep Reading...
02 December 2025
Invion Secures Expanded Photosoft Global Exclusive License
Invion Limited (IVX:AU) has announced Invion Secures Expanded Photosoft Global Exclusive LicenseDownload the PDF here. Keep Reading...
30 October 2025
Appendix 4C and Quarterly Activities Report - September 2025
Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - September 2025Download the PDF here. Keep Reading...
09 October 2025
Repayment of Lind Facility with Successful Capital Raise
Invion Limited (IVX:AU) has announced Repayment of Lind Facility with Successful Capital RaiseDownload the PDF here. Keep Reading...
07 October 2025
Trading Halt
Invion Limited (IVX:AU) has announced Trading HaltDownload the PDF here. Keep Reading...
09 June
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.
(TheNewswire) Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ Kelowna, British Columbia - June 9, 2026 TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery... Keep Reading...
09 June
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing... Keep Reading...
03 June
Immunotherapy Innovations: Increasing Survival in Metastatic Breast Cancer
Metastatic breast cancer (MBC) remains incurable, with approximately only one-third of diagnosed women meeting the five year survival rate.Subtypes like triple-negative breast cancer (TNBC) or heavily pretreated hormone receptor-positive disease often come with more treatment challenges, leading... Keep Reading...
03 June
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
KELOWNA, BC / ACCESS Newswire / June 3, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it is attending the BIO International Convention ("BIO") from June 22-25 in San Diego, CA. Lexaria's attendance... Keep Reading...
02 June
5 Biggest Biotechnology ETFs in 2026
The biotech sector has made significant strides in recent years, and the market's volatility can increase the appeal of biotech ETFs. Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded... Keep Reading...
02 June
Beyond the Lab: Top-Tier Clinical Validation in Biotech Investing
Nature Medicine’s “Eleven Clinical Trials That Will Shape Medicine in 2026” highlights studies poised to influence patient care. Among the oncology selections, BriaCell Therapeutics' (TSX:BCT,NASDAQ:BCTX) pivotal Phase 3 trial of Bria-IMT™ stands out as a rare entry. This feature underscores the... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00